Trials  	Trials  	 NNS	O
with  	with  	 IN	O
impact  	impact  	 NN	O
on  	on  	 IN	O
clinical  	clinical  	 JJ	B-NP
management 	management 	 NN	I-NP
:  	:  	 :	O
first  	first  	 JJ	O
line  	line  	 NN	B-NP
Advanced-stage  	Advanced-stage  	 JJ	I-NP
epithelial  	epithelial  	 JJ	I-NP
ovarian  	ovarian  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
is  	is  	 VBZ	O
generally  	generally  	 RB	O
managed  	managed  	 VBN	O
with  	with  	 IN	O
cytoreductive  	cytoreductive  	 JJ	B-NP
surgery  	surgery  	 NN	I-NP
and  	and  	 CC	O
chemotherapy  	chemotherapy  	 VBP	O
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
carboplatin  	carboplatin  	 NN	B-NP
and  	and  	 CC	O
paclitaxel 	paclitaxel 	 NN	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
initially  	initially  	 RB	O
responsive 	responsive 	 JJ	O
,  	,  	 ,	O
most  	most  	 RBS	O
tumors  	tumors  	 JJ	O
recur  	recur  	 NN	O
and  	and  	 CC	O
demonstrate  	demonstrate  	 VB	O
progressive  	progressive  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
resistance 	resistance 	 NN	I-NP
.  	.  	 .	O
During  	During  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
20  	20  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
many  	many  	 JJ	O
thousands  	thousands  	 NNS	O
of  	of  	 IN	O
women  	women  	 NNS	O
have  	have  	 VBP	O
participated  	participated  	 VBN	O
in  	in  	 IN	O
international  	international  	 JJ	O
front-line  	front-line  	 JJ	B-NP
phase  	phase  	 NN	I-NP
3  	3  	 CD	O
trials  	trials  	 NNS	O
that  	that  	 WDT	O
have  	have  	 VBP	O
contributed  	contributed  	 VBN	O
to  	to  	 TO	O
our  	our  	 PRP$	O
understanding  	understanding  	 NN	O
of  	of  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
biology  	biology  	 NN	I-NP
and  	and  	 CC	O
helped  	helped  	 VBD	O
to  	to  	 TO	O
define  	define  	 VB	O
optimal  	optimal  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
Emerging  	Emerging  	 VBG	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
these  	these  	 DT	O
trials  	trials  	 NNS	O
need  	need  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
interpreted  	interpreted  	 VBN	O
within  	within  	 IN	O
an  	an  	 DT	O
evolving  	evolving  	 JJ	O
paradigm  	paradigm  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	B-NP
biology 	biology 	 NN	I-NP
,  	,  	 ,	O
disease  	disease  	 NN	B-NP
management 	management 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
availability  	availability  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
resources 	resources 	 NNS	I-NP
.  	.  	 .	O
Survey  	Survey  	 NN	O
of  	of  	 IN	O
recent  	recent  	 JJ	O
phase  	phase  	 NN	O
3  	3  	 CD	O
trials  	trials  	 NNS	O
and  	and  	 CC	O
emerging  	emerging  	 VBG	B-NP
principles  	principles  	 NNS	I-NP
of  	of  	 IN	I-NP
ovarian  	ovarian  	 JJ	I-NP
tumor  	tumor  	 NN	I-NP
biology 	biology 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
adding  	adding  	 VBG	O
a  	a  	 DT	O
third  	third  	 JJ	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agent  	agent  	 NN	I-NP
improves  	improves  	 VBZ	O
clinical  	clinical  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
weekly  	weekly  	 JJ	O
dose-dense  	dose-dense  	 JJ	B-NP
scheduling  	scheduling  	 NN	I-NP
of  	of  	 IN	I-NP
paclitaxel  	paclitaxel  	 NN	I-NP
appears  	appears  	 VBZ	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
standard  	standard  	 JJ	O
dosing 	dosing 	 NN	O
.  	.  	 .	O
Primary  	Primary  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
with  	with  	 IN	O
carboplatin  	carboplatin  	 NN	B-NP
and  	and  	 CC	O
paclitaxel  	paclitaxel  	 NN	B-NP
remains  	remains  	 VBZ	O
a  	a  	 DT	O
well-tolerated  	well-tolerated  	 JJ	O
standard  	standard  	 JJ	O
regimen 	regimen 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
option  	option  	 NN	O
of  	of  	 IN	O
weekly  	weekly  	 JJ	O
paclitaxel  	paclitaxel  	 JJ	B-NP
dosing 	dosing 	 NN	I-NP
.  	.  	 .	O
Data  	Data  	 NNS	O
are  	are  	 VBP	O
awaited  	awaited  	 VBN	O
from  	from  	 IN	O
completed  	completed  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
incorporating  	incorporating  	 VBG	I-NP
bevacizumab 	bevacizumab 	 NNS	I-NP
.  	.  	 .	O
Emerging  	Emerging  	 VBG	O
biological  	biological  	 JJ	B-NP
paradigms  	paradigms  	 NN	I-NP
will  	will  	 MD	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
individualized  	individualized  	 VB	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
future 	future 	 NN	O
.  	.  	 .	O
